<p>在 Google 搜索和 AI 答案中查看更多來自 StockTitan 的信息。將 StockTitan 添加為首選來源 · 打開 Google</p>
<p>在 Google 上添加</p>
<p>北卡羅來納州達勒姆，2026 年 6 月 10 日（全球新聞稿）—— Humacyte, Inc.（納斯達克：HUMA）是一家商業階段的生物技術平台公司，開發可普遍植入的生物工程人類組織，今天宣佈以每股 1.05 美元的公開發行價格定價 47,619,048 股普通股的承銷公開發行。預計此次發行的總毛收益為 5000 萬美元，未扣除 Humacyte 應支付的承銷折扣和佣金及其他發行費用。此次發行的結束預計將在 2026 年 6 月 12 日左右進行，具體取決於滿足慣例的結束條件。此外，Humacyte 已向承銷商授予 30 天的選擇權，以按公開發行價格購買最多 7,142,857 股 Humacyte 的普通股，扣除承銷折扣和佣金。所有普通股均由 Humacyte 出售。</p>
<p>巴克萊銀行、BTIG 和 Titan Partners（美國資本合夥公司的一個部門）作為此次發行的聯合賬簿管理人。</p>
<p>Humacyte 打算將其從此次發行中獲得的淨收益用於資助 Symvess® 的商業化、計劃提交生物製品許可證申請補充的血液透析適應症及相關活動、開發其管道中的產品候選者，以及用於營運資金和一般企業用途。</p>
<p>在 2025 年 9 月 12 日，已向證券交易委員會（“SEC”）提交了一份 S-3 表格的貨架註冊聲明（編號 333-290231），並於 2025 年 9 月 22 日獲得 SEC 的有效聲明。證券是通過與此次發行相關的招股説明書補充和附帶招股説明書進行發行的，這些文件構成註冊聲明的一部分。與此次發行相關的初步招股説明書補充及附帶招股説明書已於 2026 年 6 月 10 日提交給 SEC，並可在 SEC 的網站 www.sec.gov 上獲取。與此次發行相關的最終招股説明書補充及附帶招股説明書將提交給 SEC，並將在 SEC 的網站 www.sec.gov 上提供。在投資此次發行之前，您應完整閲讀與此次發行相關的每份招股説明書補充及附帶招股説明書，以及 Humacyte 向 SEC 提交的其他文件，這些文件在招股説明書補充及附帶招股説明書中引用，提供有關 Humacyte 和此次發行的更多信息。最終招股説明書補充的副本（可用時）及與此次發行相關的附帶招股説明書可從巴克萊資本公司（Barclays Capital Inc.），郵寄地址：Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717，電話：(888) 603-5847，或通過電子郵件 barclaysprospectus@broadridge.com；BTIG, LLC，地址：65 East 55th Street, New York, New York 10022，電話：(212) 593-7555，或通過電子郵件 ProspectusDelivery@btig.com；或 Titan Partners Group LLC（美國資本合夥公司的一個部門），地址：4 World Trade Center, 49th Floor, New York, NY 10007，電話：(929) 833-1246，或通過電子郵件 prospectus@titanpartnersgrp.com 獲取。</p>
<p>本新聞稿不構成出售或招攬購買此處所述任何證券的要約，也不應在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的證券法下未註冊或資格不符，則此類要約、招攬或銷售將是非法的。</p>
<p><strong>關於 Humacyte</strong></p>
<p>Humacyte, Inc.（納斯達克：HUMA）是一家商業階段的生物技術平台公司，開發可普遍植入的生物工程人類組織，並於 2025 年第一季度開始在美國商業推出其首個 FDA 批准的產品 Symvess。Humacyte 正在開創可即用的、普遍植入的生物工程人類組織、先進組織構造和器官系統的開發與製造，旨在改善患者的生活並改變醫學實踐。Humacyte 正在利用其新穎、可擴展的技術平台，開發專有的生物工程無細胞人類組織，用於治療多種解剖部位的疾病和病症，涵蓋多個治療領域。</p>
<p>除美國食品和藥物管理局（“FDA”）在肢體血管創傷適應症下的批准外，無細胞組織工程血管（“ATEV”）為一種研究性產品，尚未獲得 FDA 或任何其他監管機構的銷售批准。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含基於信念和假設以及當前可用信息的前瞻性聲明。在某些情況下，您可以通過以下詞語識別前瞻性聲明：“可能”、“將”、“能夠”、“會”、“應該”、“期望”、“打算”、“計劃”、“預期”、“相信”、“估計”、“預測”、“項目”、“潛在”、“繼續”、“正在進行” 或這些術語的否定形式或其他可比術語，儘管並非所有前瞻性聲明都包含這些詞。這些聲明涉及風險、不確定性和其他因素，可能導致實際結果、活動水平、表現或成就與這些前瞻性聲明所表達或暗示的信息有實質性差異。儘管 Humacyte 相信其對本新聞稿中每個前瞻性聲明都有合理的依據，但 Humacyte 提醒您，這些聲明是基於其當前已知的事實和因素的組合以及對未來的預測，Humacyte 對此無法確定。本新聞稿中的前瞻性聲明包括但不限於關於發行的慣常成交條件的時間和滿足情況以及預計的發行收益使用情況的聲明。Humacyte 無法保證本新聞稿中的前瞻性聲明將被證明是準確的。這些前瞻性聲明受到許多重大風險和不確定性的影響，這些風險和不確定性可能導致實際結果與預期結果有實質性差異，包括但不限於適用法律或法規的變化，Humacyte 可能受到其他經濟、商業和/或競爭因素的不利影響的可能性，以及其他風險和不確定性，包括在 Humacyte 截至 2025 年 12 月 31 日的年度報告 Form 10-K 和截至 2026 年 3 月 31 日的季度報告 Form 10-Q 中描述的 “風險因素” 標題下的風險，這些報告均已由 Humacyte 提交給 SEC，以及未來的 SEC 文件。這些因素大多數超出了 Humacyte 的控制範圍，且難以預測。此外，如果前瞻性聲明被證明不準確，則不準確性可能是實質性的。鑑於這些前瞻性聲明中的重大不確定性，您不應將這些聲明視為 Humacyte 或任何其他人對 Humacyte 將在任何特定時間框架內或根本上實現其目標和計劃的陳述或保證。除法律要求外，Humacyte 目前無意更新本新聞稿中的任何前瞻性聲明。因此，您不應依賴這些前瞻性聲明作為 Humacyte 在本新聞稿日期之後的任何日期的觀點。</p>
<p><strong>Humacyte 投資者聯繫：</strong></p>
<p>Joyce Allaire</p>
<p>LifeSci Advisors LLC</p>
<p>+1-617-435-6602</p>
<p>jallaire@lifesciadvisors.com</p>
<p>investors@humacyte.com</p>
<p><strong>Humacyte 媒體聯繫：</strong></p>
<p>Rich Luchette</p>
<p>Precision Strategies</p>
<p>+1-202-845-3924</p>
<p>rich@precisionstrategies.com</p>
<p>media@humacyte.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5UTTFOaU0zTmpVMk9UVXdJekl5TURrME16WT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5UTTFOaU0zTmpVMk9UVXdJekl5TURrME16WT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png"/></p>

HUMA

巴克萊銀行

<p>Humacyte, Inc.（納斯達克代碼：HUMA）宣佈以每股 1.05 美元的價格公開發行 47,619,048 股普通股，籌集約 5000 萬美元的總收入。預計交易將在 2026 年 6 月 12 日左右完成。淨收入將用於 Symvess®的商業化、BLA 補充申請、管道開發和營運資金。巴克萊銀行、BTIG 和 Titan Partners 為聯合主承銷商</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 答案中查看更多來自 StockTitan 的信息。將 StockTitan 添加為首選來源 · 打開 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.</p>
<div class="lb-trans"><p>北卡羅來納州達勒姆，2026 年 6 月 10 日（全球新聞稿）—— Humacyte, Inc.（納斯達克：HUMA）是一家商業階段的生物技術平台公司，開發可普遍植入的生物工程人類組織，今天宣佈以每股 1.05 美元的公開發行價格定價 47,619,048 股普通股的承銷公開發行。預計此次發行的總毛收益為 5000 萬美元，未扣除 Humacyte 應支付的承銷折扣和佣金及其他發行費用。此次發行的結束預計將在 2026 年 6 月 12 日左右進行，具體取決於滿足慣例的結束條件。此外，Humacyte 已向承銷商授予 30 天的選擇權，以按公開發行價格購買最多 7,142,857 股 Humacyte 的普通股，扣除承銷折扣和佣金。所有普通股均由 Humacyte 出售。</p>
</div><p>Barclays, BTIG and Titan Partners, a division of American Capital Partners, are acting as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>巴克萊銀行、BTIG 和 Titan Partners（美國資本合夥公司的一個部門）作為此次發行的聯合賬簿管理人。</p>
</div><p>Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of Symvess®, the planned filing of a Biologics License Application supplement in a hemodialysis indication and related activities, the development of the product candidates in its pipeline and for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Humacyte 打算將其從此次發行中獲得的淨收益用於資助 Symvess® 的商業化、計劃提交生物製品許可證申請補充的血液透析適應症及相關活動、開發其管道中的產品候選者，以及用於營運資金和一般企業用途。</p>
</div><p>A shelf registration statement on Form S-3 (No. 333-290231) was previously filed with the Securities and Exchange Commission (the “SEC”) on September 12, 2025 and declared effective by the SEC on September 22, 2025. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on June 10, 2026 and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that Humacyte has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about Humacyte and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com; BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at ProspectusDelivery@btig.com; or Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.</p>
<div class="lb-trans"><p>在 2025 年 9 月 12 日，已向證券交易委員會（“SEC”）提交了一份 S-3 表格的貨架註冊聲明（編號 333-290231），並於 2025 年 9 月 22 日獲得 SEC 的有效聲明。證券是通過與此次發行相關的招股説明書補充和附帶招股説明書進行發行的，這些文件構成註冊聲明的一部分。與此次發行相關的初步招股説明書補充及附帶招股説明書已於 2026 年 6 月 10 日提交給 SEC，並可在 SEC 的網站 www.sec.gov 上獲取。與此次發行相關的最終招股説明書補充及附帶招股説明書將提交給 SEC，並將在 SEC 的網站 www.sec.gov 上提供。在投資此次發行之前，您應完整閲讀與此次發行相關的每份招股説明書補充及附帶招股説明書，以及 Humacyte 向 SEC 提交的其他文件，這些文件在招股説明書補充及附帶招股説明書中引用，提供有關 Humacyte 和此次發行的更多信息。最終招股説明書補充的副本（可用時）及與此次發行相關的附帶招股説明書可從巴克萊資本公司（Barclays Capital Inc.），郵寄地址：Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717，電話：(888) 603-5847，或通過電子郵件 barclaysprospectus@broadridge.com；BTIG, LLC，地址：65 East 55th Street, New York, New York 10022，電話：(212) 593-7555，或通過電子郵件 ProspectusDelivery@btig.com；或 Titan Partners Group LLC（美國資本合夥公司的一個部門），地址：4 World Trade Center, 49th Floor, New York, NY 10007，電話：(929) 833-1246，或通過電子郵件 prospectus@titanpartnersgrp.com 獲取。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售或招攬購買此處所述任何證券的要約，也不應在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的證券法下未註冊或資格不符，則此類要約、招攬或銷售將是非法的。</p>
</div><p><strong>About Humacyte</strong></p>
<div class="lb-trans"><p><strong>關於 Humacyte</strong></p>
</div><p>Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of Symvess, its first FDA-approved product. Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.</p>
<div class="lb-trans"><p>Humacyte, Inc.（納斯達克：HUMA）是一家商業階段的生物技術平台公司，開發可普遍植入的生物工程人類組織，並於 2025 年第一季度開始在美國商業推出其首個 FDA 批准的產品 Symvess。Humacyte 正在開創可即用的、普遍植入的生物工程人類組織、先進組織構造和器官系統的開發與製造，旨在改善患者的生活並改變醫學實踐。Humacyte 正在利用其新穎、可擴展的技術平台，開發專有的生物工程無細胞人類組織，用於治療多種解剖部位的疾病和病症，涵蓋多個治療領域。</p>
</div><p>For uses other than the U.S. Food and Drug Administration (“FDA”) approval in the extremity vascular trauma indication, the acellular tissue engineered vessel (“ATEV”) is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.</p>
<div class="lb-trans"><p>除美國食品和藥物管理局（“FDA”）在肢體血管創傷適應症下的批准外，無細胞組織工程血管（“ATEV”）為一種研究性產品，尚未獲得 FDA 或任何其他監管機構的銷售批准。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Humacyte believes that it has a reasonable basis for each forward-looking statement contained in this press release, Humacyte cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which Humacyte cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and satisfaction of customary closing conditions of the offering and the anticipated use of proceeds from the offering. Humacyte cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in Humacyte’s Annual Report on Form 10-K for the year ended December 31, 2025 and in Humacyte’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Humacyte or any other person that Humacyte will achieve its objectives and plans in any specified time frame, or at all. Except as required by law, Humacyte has no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing Humacyte’s views as of any date subsequent to the date of this press release.</p>
<div class="lb-trans"><p>本新聞稿包含基於信念和假設以及當前可用信息的前瞻性聲明。在某些情況下，您可以通過以下詞語識別前瞻性聲明：“可能”、“將”、“能夠”、“會”、“應該”、“期望”、“打算”、“計劃”、“預期”、“相信”、“估計”、“預測”、“項目”、“潛在”、“繼續”、“正在進行” 或這些術語的否定形式或其他可比術語，儘管並非所有前瞻性聲明都包含這些詞。這些聲明涉及風險、不確定性和其他因素，可能導致實際結果、活動水平、表現或成就與這些前瞻性聲明所表達或暗示的信息有實質性差異。儘管 Humacyte 相信其對本新聞稿中每個前瞻性聲明都有合理的依據，但 Humacyte 提醒您，這些聲明是基於其當前已知的事實和因素的組合以及對未來的預測，Humacyte 對此無法確定。本新聞稿中的前瞻性聲明包括但不限於關於發行的慣常成交條件的時間和滿足情況以及預計的發行收益使用情況的聲明。Humacyte 無法保證本新聞稿中的前瞻性聲明將被證明是準確的。這些前瞻性聲明受到許多重大風險和不確定性的影響，這些風險和不確定性可能導致實際結果與預期結果有實質性差異，包括但不限於適用法律或法規的變化，Humacyte 可能受到其他經濟、商業和/或競爭因素的不利影響的可能性，以及其他風險和不確定性，包括在 Humacyte 截至 2025 年 12 月 31 日的年度報告 Form 10-K 和截至 2026 年 3 月 31 日的季度報告 Form 10-Q 中描述的 “風險因素” 標題下的風險，這些報告均已由 Humacyte 提交給 SEC，以及未來的 SEC 文件。這些因素大多數超出了 Humacyte 的控制範圍，且難以預測。此外，如果前瞻性聲明被證明不準確，則不準確性可能是實質性的。鑑於這些前瞻性聲明中的重大不確定性，您不應將這些聲明視為 Humacyte 或任何其他人對 Humacyte 將在任何特定時間框架內或根本上實現其目標和計劃的陳述或保證。除法律要求外，Humacyte 目前無意更新本新聞稿中的任何前瞻性聲明。因此，您不應依賴這些前瞻性聲明作為 Humacyte 在本新聞稿日期之後的任何日期的觀點。</p>
</div><p><strong>Humacyte Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>Humacyte 投資者聯繫：</strong></p>
</div><p>Joyce Allaire</p>
<div class="lb-trans"><p>Joyce Allaire</p>
</div><p>LifeSci Advisors LLC</p>
<div class="lb-trans"><p>LifeSci Advisors LLC</p>
</div><p>+1-617-435-6602</p>
<div class="lb-trans"><p>+1-617-435-6602</p>
</div><p>jallaire@lifesciadvisors.com</p>
<div class="lb-trans"><p>jallaire@lifesciadvisors.com</p>
</div><p>investors@humacyte.com</p>
<div class="lb-trans"><p>investors@humacyte.com</p>
</div><p><strong>Humacyte Media Contact:</strong></p>
<div class="lb-trans"><p><strong>Humacyte 媒體聯繫：</strong></p>
</div><p>Rich Luchette</p>
<div class="lb-trans"><p>Rich Luchette</p>
</div><p>Precision Strategies</p>
<div class="lb-trans"><p>Precision Strategies</p>
</div><p>+1-202-845-3924</p>
<div class="lb-trans"><p>+1-202-845-3924</p>
</div><p>rich@precisionstrategies.com</p>
<div class="lb-trans"><p>rich@precisionstrategies.com</p>
</div><p>media@humacyte.com</p>
<div class="lb-trans"><p>media@humacyte.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek5UTTFOaU0zTmpVMk9UVXdJekl5TURrME16WT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTczNTM1NiM3NjU2OTUwIzIyMDk0MzY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MWM5ZTVmMWQtYTMwZi00ZTE3LWI5ZjYtM2VkNDAwMzkyMjVhLTEyMjA5ODktMjAyNi0wNi0xMS1lbg==/tiny/Humacyte-Inc.png"/></p>

Humacyte, Inc. 宣佈其普通股公開發行的定價 | HUMA 股票新聞